Pediatric sepsis responds to Vitamin D — faster forms likely work better

Question: Can Sepsis in children be treated by fast-acting Vitamin D?

Claude AI - April 2027

Short answer: yes, with caveats — the evidence supports rapid vitamin D repletion as adjunctive therapy in pediatric sepsis, particularly in deficient children, but it's not a replacement for antibiotics and supportive care.

RCT trial with 150,000 IU: reduced Septic Shock from 20% to 7%

Wang et al. 2020 (PICU, China, n=109) — the most directly relevant pediatric RCT. Children with vitamin D deficiency and sepsis received a single 150,000 IU oral cholecalciferol bolus or placebo. Ang-II, IL-6, and TNF-α concentrations were all reduced after vitamin D supplementation. The cv-SOFA score (1.76 ± 0.8 vs. 2.3 ± 1.1) and incidence of septic shock (7% vs. 20%) were lower in the treatment group than in the control group. The duration of ventilation and mortality rates did not differ between two groups. A 13-percentage-point absolute reduction in progression to septic shock is clinically meaningful even if mortality wasn't powered.

Neonatal sepsis trials are more modest in dosing — typically 400 vs 800 IU/day cholecalciferol — and show CRP/IL-6 improvements but with the obvious limitation that those doses don't rapidly raise 25(OH)D.

VITdAL-PICU (Children's Hospital of Eastern Ontario, NCT02452762) established that high loading doses can safely and rapidly normalize 25(OH)D in critically ill children, providing the dosing groundwork for the larger VITdALIZE-KIDS Phase III trial that is now testing whether rapid repletion improves PICU outcomes.

Why "fast-acting" matters here

Cholecalciferol bolus dosing works but takes days for the liver to 25-hydroxylate it. Sepsis kills on a timescale of hours. Two routes get around this:

  1. Calcifediol (25-OH-D3) — bypasses hepatic hydroxylation. Oral calcifediol increases the serum 25(OH)D levels more rapidly and is about 3.2-fold more potent than cholecalciferol. The Castillo Córdoba COVID-19 trial in adults showed dramatic ICU-admission reductions, and adult sepsis data (Quraishi et al. with 200,000–400,000 IU cholecalciferol) showed High-dose cholecalciferol supplementation rapidly and safely improves 25-hydroxyvitamin D and bioavailable 25-hydroxyvitamin D levels in patients with severe sepsis or septic shock. Changes in bioavailable 25-hydroxyvitamin D are associated with concomitant increases in circulating LL-37 levels. That cathelicidin signal is the mechanistic link to bacterial killing.

  2. Liposomal/nanoemulsion D3 — your area of recent research. The PK case for these in deficient populations is the same case as for calcifediol: get circulating 25(OH)D into the immunologically useful range (>50 ng/mL) within hours rather than days. No published pediatric sepsis RCT yet uses these forms specifically — that's a real gap in the literature.

Mechanism (why it works at all)

The cathelicidin/LL-37 pathway requires adequate intracellular 25(OH)D for macrophages to mount their antimicrobial response. Septic patients are typically deficient on admission, and their VDBP levels drop, further reducing bioavailable 25(OH)D. Fixing the substrate problem fast lets the innate immune machinery actually work — which is why Leaf et al. saw cathelicidin mRNA changes within 24 hours after IV calcitriol in adult sepsis.

* The honest caveats*

  • Pediatric trial sample sizes are small (~100 each). The shock-incidence signal is real but needs replication.
  • Mortality benefit has not been demonstrated in children — only in the severe-deficiency subgroup of adult VITdAL-ICU.
  • Calcifediol is not widely available pediatrically in the US; off-label adult formulations don't have pediatric dose-finding data.
  • This is adjunctive. Nothing replaces source control, antibiotics, and resuscitation.

Related in VitaminDWiki